Using a specialized lab technique, scientists identified early cellular changes that may help drive lung scarring in ...

Tyvaso significantly improved a measure of lung function for IPF patients in a Phase 3 trial, which top-line data showed met ...

Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.

Charlene Marshall is a fiercely independent 30-something-year-old who can’t sit still. She loves coffee, wine tasting, playing with her dog, and spending time on the beach with her family. She’s a ...

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs, leading to breathing difficulties, dry cough, muscle aches, and unintended weight loss. Because these symptoms also are ...

Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary fibrosis (IPF) and chronic cough. That’s ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs. Scar tissue development can interfere with the lungs’ ability to deliver oxygen to the bloodstream, as well as with ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...